Opinion|Videos|October 25, 2024
Vaccine Hesitancy and Patient Counseling Techniques
Author(s)Carrie Koenigsfeld, PharmD, FAPhA
Key Takeaways
- Vaccine hesitancy in older adults is driven by concerns about safety, efficacy, necessity, awareness, and cost of RSV vaccines.
- Pharmacists should provide clear, evidence-based information and personalized counseling to address vaccine hesitancy effectively.
Carrie Koenigsfeld, PharmD, FAPhA, discusses her experience with concerns and perceptions contributing to RSV vaccine hesitancy among older adults, such as safety, efficacy, necessity, awareness, and cost, and she explores how pharmacists can effectively counsel patients and caregivers about RSV vaccines while tailoring communication strategies to educate older adults with low health literacy.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- In your experience, what concerns or perceptions have you identified (ie, safety, efficacy, necessity, awareness, cost) as contributing to RSV vaccine hesitancy among older adults?
- How can pharmacists counsel patients and caregivers about RSV vaccines to address these concerns effectively?
- How can pharmacists tailor their communication strategies to effectively reach and educate older adults with low health literacy?
Advertisement
Related to this article
September’s pain management coverage examined postoperative nonopioid options, lessons from sickle cell pain research, and pharmacists’ experiences with controlled-substance prescribing.
September’s hematology coverage examined a new definition of myeloma cure, patient preferences for treatment delivery, and emerging strategies for deepening responses.
Indirect comparison links orforglipron 17.2 mg to 1.5% more weight loss and 0.3% more A1C lowering than oral semaglutide 25 mg in adults with type 2 diabetes.
Pharmacists can help overcome influenza vaccine hesitancy by correcting common misconceptions, routinely asking every patient about vaccination, and leveraging their standing as trusted health care professionals.
September oncology coverage highlighted new breast and kidney cancer combinations, updated lung cancer labeling, and emerging evidence connecting antibiotic exposure with CAR T-cell outcomes.
Phase 3 TRIUMPH-2 data presented at EASD show HbA1c reductions up to 1.6%, with GI effects, hypotension, and dysesthesia as key counseling points.
In a FINE-HEART analysis, cancer history raised the risk of death and hospitalization but did not blunt finerenone's cardiovascular and kidney benefits.
Hemoglobin, platelets, bleeding, pericardial effusions, and intrapulmonary shunting top the monitoring list for patients with pulmonary arterial hypertension (PAH) starting with sotatercept, according to Vallerie McLaughlin, MD.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Tiratricol, First Treatment for MCT8 Deficiency
2
Retatrutide Cuts Weight Up to 18.8% in Adults With T2D, Obesity
3
Intensive Chemotherapy in Combination With Quizartinib Versus Midostaurin for FLT3-ITD Mutated Acute Myeloid Leukemia: A Multicenter Cohort Study
4
Pharmacists Can Close CKD Medication Adherence Gaps, PHTI Says
5